

Antonio Mas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8408494/publications.pdf>

Version: 2024-02-01

60
papers

1,440
citations

331670

21
h-index

345221

36
g-index

62
all docs

62
docs citations

62
times ranked

1436
citing authors

#	ARTICLE	IF	CITATIONS
1	Interferon α for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1996, 23, 585-591.	5.8	187
2	Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. <i>EMBO Journal</i> , 2000, 19, 5752-5761.	7.8	100
3	Unfinished Stories on Viral Quasispecies and Darwinian Views of Evolution. <i>Journal of Molecular Biology</i> , 2010, 397, 865-877.	4.2	82
4	Quasispecies as a matter of fact: Viruses and beyond. <i>Virus Research</i> , 2011, 162, 203-215.	2.2	65
5	Analysis of pol Gene Heterogeneity, Viral Quasispecies, and Drug Resistance in Individuals Infected with Group O Strains of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 1998, 72, 9002-9015.	3.4	64
6	Host Deadenylation-Dependent mRNA Decapping Factors Are Required for a Key Step in Brome Mosaic Virus RNA Replication. <i>Journal of Virology</i> , 2006, 80, 246-251.	3.4	56
7	Hepatitis E Virus in Industrialized Countries: The Silent Threat. <i>BioMed Research International</i> , 2016, 2016, 1-17.	1.9	52
8	Multidrug-resistant HIV-1 Reverse Transcriptase: Involvement of Ribonucleotide-dependent Phosphorolysis in Cross-resistance to Nucleoside Analogue Inhibitors. <i>Journal of Molecular Biology</i> , 2002, 323, 181-197.	4.2	44
9	Highly heterogeneous mutation rates in the hepatitis C virus genome. <i>Nature Microbiology</i> , 2016, 1, 16045.	13.3	44
10	Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance. <i>Oncotarget</i> , 2015, 6, 15551-15565.	1.8	43
11	Molecular Determinants of Multi-nucleoside Analogue Resistance in HIV-1 Reverse Transcriptases Containing a Dipeptide Insertion in the Fingers Subdomain. <i>Journal of Biological Chemistry</i> , 2004, 279, 24569-24577.	3.4	42
12	LSm1-7 complexes bind to specific sites in viral RNA genomes and regulate their translation and replication. <i>Rna</i> , 2010, 16, 817-827.	3.5	41
13	Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation. <i>Journal of Virology</i> , 2002, 76, 10546-10552.	3.4	40
14	First Case of HIV-1 Group O Infection in Spain. <i>Vox Sanguinis</i> , 1996, 71, 66-66.	1.5	34
15	Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. <i>Virus Research</i> , 2000, 66, 13-26.	2.2	34
16	Virus population dynamics, fitness variations and the control of viral disease: an update. , 2001, 57, 77-115.		34
17	Functional Characterization of Chimeric Reverse Transcriptases with Polypeptide Subunits of Highly Divergent HIV-1 Group M and O Strains. <i>Journal of Biological Chemistry</i> , 2001, 276, 27470-27479.	3.4	32
18	Prognostic Value of a CCR5 Defective Allele in Pediatric HIV-1 Infection. <i>Molecular Medicine</i> , 2000, 6, 28-36.	4.4	31

#	ARTICLE	IF	CITATIONS
19	LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. <i>Virus Research</i> , 1998, 57, 11-20.	2.2	27
20	The Effect of 1,25-Dihydroxyvitamin D3 on Insulin Binding, Insulin Receptor mRNA Levels, and Isotype RNA Pattern in U-937 Human Promonocytic Cells. <i>Experimental Cell Research</i> , 1995, 217, 189-194.	2.6	26
21	Information catastrophe in RNA viruses through replication thresholds. <i>Journal of Theoretical Biology</i> , 2006, 240, 353-359.	1.7	24
22	De Novo Polymerase Activity and Oligomerization of Hepatitis C Virus RNA-Dependent RNA-Polymerases from Genotypes 1 to 5. <i>PLoS ONE</i> , 2011, 6, e18515.	2.5	23
23	Sequence Note:envGene Characterization of the First HIV Type 1 Group O Spanish Isolate. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1647-1649.	1.1	21
24	The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load. <i>Journal of Infection</i> , 1998, 36, 307-311.	3.3	20
25	Hepatitis C virus population analysis of a single-source nosocomial outbreak reveals an inverse correlation between viral load and quasispecies complexity. <i>Journal of General Virology</i> , 2004, 85, 3619-3626.	2.9	19
26	Cytotoxic T-Lymphocyte Responses to HIV-1 Reverse Transcriptase (Review). <i>Viral Immunology</i> , 1998, 11, 167-181.	1.3	17
27	A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. <i>Journal of Infection</i> , 1997, 35, 225-230.	3.3	15
28	Xenopus Xp54 and Human RCK/p54 Helicases Functionally Replace Yeast Dhh1p in Brome Mosaic Virus RNA Replication. <i>Journal of Virology</i> , 2007, 81, 4378-4380.	3.4	15
29	Quantitation of Human Immunodeficiency Virus Type 1 Group O Load in Plasma by Measuring Reverse Transcriptase Activity. <i>Journal of Clinical Microbiology</i> , 2000, 38, 402-405.	3.9	12
30	Phylogeny of HIV Type 1 Group O Isolates Based on env Gene Sequences. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 769-773.	1.1	11
31	Epidemiology of HTLV-I Infection in Spain. <i>International Journal of Epidemiology</i> , 1996, 25, 443-449.	1.9	10
32	Reliability of a new recombinant immunoblot assay (RIBA HIV-1/HIV-2 SIA) as a supplemental (confirmatory) test for HIV-1 and HIV-2 infections. <i>Transfusion Science</i> , 1997, 18, 63-69.	0.6	10
33	CCR5 genotype and HIV-1 infection in perinatally-exposed infants. <i>Journal of Infection</i> , 1999, 38, 9-11.	3.3	10
34	Prevalence and Genetic Heterogeneity of the Reverse Transcriptase T69S-S-X Insertion in Pretreated HIV-Infected Patients. <i>Intervirology</i> , 2001, 44, 339-343.	2.8	10
35	Monitoring hepatitis C virus (HCV) RNA-dependent RNA polymerase oligomerization by a FRET-based in vitro system. <i>Antiviral Research</i> , 2010, 87, 57-66.	4.1	10
36	Hepatitis C virus polymeraseâ€“polymerase contact interface: Significance for virus replication and antiviral design. <i>Antiviral Research</i> , 2014, 108, 14-24.	4.1	10

#	ARTICLE	IF	CITATIONS
37	Akt Kinase Intervenes in Flavivirus Replication by Interacting with Viral Protein NS5. <i>Viruses</i> , 2021, 13, 896.	3.3	10
38	Tissue-Specific Changes in Insulin Receptor mRNA Concentrations in Dexamethasone-Treated and Adrenalectomized Rats.. <i>Endocrine Journal</i> , 1994, 41, 737-741.	1.6	9
39	Epidemiology of HIV-2 infection in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1996, 15, 383-388.	2.9	9
40	Epinephrine-Induced Reduction in Insulin Receptor mRNA Level and Stability in U-937 Human Promonocytic Cells. <i>Hormone and Metabolic Research</i> , 1998, 30, 118-122.	1.5	9
41	Tropism, Coreceptor Use, and Phylogenetic Analysis of Both the V3 Loop and the Protease Gene of Three Novel HIV-1 Group O Isolates. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 417-425.	0.3	9
42	Hepatitis C viraemia in HIV-infected patients. <i>Aids</i> , 1996, 10, 922.	2.2	8
43	Characterization of the interaction between hepatitis C virus NS5B and the human oestrogen receptor alpha. <i>Journal of General Virology</i> , 2012, 93, 780-785.	2.9	7
44	Hepatitis C Virus RNA-Dependent RNA Polymerase Interacts with the Akt/PKB Kinase and Induces Its Subcellular Relocalization. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3540-3550.	3.2	7
45	Akt Interacts with Usutu Virus Polymerase, and Its Activity Modulates Viral Replication. <i>Pathogens</i> , 2021, 10, 244.	2.8	7
46	Prevalence of zidovudine-resistant HIV-1 among rapid progressors. <i>Aids</i> , 1996, 10, 1292-1293.	2.2	6
47	Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes. <i>Journal of Medical Virology</i> , 2004, 73, 350-361.	5.0	6
48	Serial Dilutions on Synthetic Peptide-Based Assays Can Resolve Dual Seroreactivity to HIV-1 and HIV-2. <i>Vox Sanguinis</i> , 1996, 71, 67-68.	1.5	5
49	Genetic Analysis of an HIV Type 2 Subtype B Virus from a Spanish Individual with AIDS. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 899-900.	1.1	5
50	Letter to the Editor: Phylogenetic Analysis of HIV Type 2 Strains from Portugal. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 471-473.	1.1	5
51	V3-loop and nef gene sequences of HIV-1 isolates from a hemophiliac cohort with long-term non-progressive infection. <i>Aids</i> , 1999, 13, 532.	2.2	5
52	Polymerase Activity, Protein-Protein Interaction, and Cellular Localization of the Usutu Virus NS5 Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	4
53	Short-term efficacy and safety of stavudine in pretreated HIV-infected patients. <i>Antiviral Therapy</i> , 1997, 2, 185-9.	1.0	4
54	Guanosine inhibits hepatitis C virus replication and increases indel frequencies, associated with altered intracellular nucleotide pools. <i>PLoS Pathogens</i> , 2022, 18, e1010210.	4.7	3

#	ARTICLE	IF	CITATIONS
55	Circulating HIV-1 Serotypes in Spain. <i>Vox Sanguinis</i> , 1996, 70, 236-237.	1.5	2
56	Akt Phosphorylation of Hepatitis C Virus NS5B Regulates Polymerase Activity and Hepatitis C Virus Infection. <i>Frontiers in Microbiology</i> , 2021, 12, 754664.	3.5	2
57	Similar HIV-1 evolution and immunological responses at 10 years despite several therapeutic strategies and host HLA Types. <i>Journal of Medical Virology</i> , 2004, 73, 495-501.	5.0	1
58	Population Diversity and its Relationship with Infectious and Tumor Diseases. <i>Current Immunology Reviews</i> , 2011, 7, 50-56.	1.2	0
59	The HCV Replicase Interactome. <i>American Journal of Virology</i> , 2016, 5, 8-14.	0.4	0
60	The Ultrasensitive NASBA Assay for Quantifying HIV-1 Viral Load. <i>Antiviral Therapy</i> , 1998, 3, 43-44.	1.0	0